pillbase.ru

Insulin Degludec

Active substance: Insulin degludec

INJECTION, SOLUTION · INSULIN DEGLUDEC 100 U/mL

United StatesActive

Marketing holder: Novo Nordisk Pharma, Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 3
  • Ryzodeg
    insulin aspart, insulin degludec
    EMEA/H/C/002499
    Novo Nordisk A/S
  • Tresiba
    insulin degludec
    EMEA/H/C/002498
    Novo Nordisk A/S
  • Xultophy
    insulin degludec, liraglutide
    EMEA/H/C/002647
    Novo Nordisk A/S
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-2e97-715a-8b92-275e5f9a49e1,01a1208e-40ba-7221-989e-20443fff7f6a,01a1208e-5cb6-7a8c-b0a3-10f6a611c65f,01a1208f-abd6-7a28-9a18-ce1409399a9d,01a12093-88fb-74f4-888d-7b131cb75f5d;count=10 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
73070-403
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 73070-403 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 73070-403 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 73070-403 · Verified 2026-10-09 · open in source